Two European firms ally in PET

Article

Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose)

Alliance Medical of Oxfordshire and M2i of Dublin have formed a joint venture to produce and distribute PET radiopharmaceuticals in the U.K. The new company, called Molecular Imaging Services, will focus on the production of F-18 FDG (fluorodeoxyglucose) through a series of dedicated radiopharmaceutical production units. These units will serve both hospital-based PET facilities and mobile PET scanners. Alliance Medical operates two PET scanners in the U.K.: a stationary unit at a facility located in London and a mobile PET scanner serving three hospitals. The mobile PET will soon begin serving a fourth hospital.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.